Cancer drug prices slashed up to 86% in a year: NPPA

New Delhi, March 08, 2017: Drug pricing regulator NPPA has slashed price of cancer drugs by up to 86 per cent since March last year providing relief to lakhs of patients.

The drugs include Iressa of AstraZeneca Pharma India whose price has been bought down from ₹29,259 to ₹3,977, a reduction of 86 per cent and Dr Reddy’s Grafeel — price has been slashed by 41 per cent, it said.

The reduction is in the price range of 86 per cent to 13 per cent, the NPPA said.

The other pharma players are Natco Pharma and Emcure Pharmaceuticals among others, it added.

In the diabetes segment also, there has been reduction in prices of the drugs, the regulator said.

The prices have been reduced in the range of 42 per cent to 10 per cent, it added.

While prices of Glypride of Sun Pharma were reduced by 42 per cent, from ₹91 to ₹53 after the revision, the drugs of other players have also witnessed reduction in the prices.

The other drugs whose prices were reduced include Dr Reddy’s Glimy, Obimet of Abott India, Cetapin of Sanofi India and Lupin’s Gluconorm, it added. –PTI